TirzepatideThe active ingredient in the popular weight loss drug Zepbound has been shown to reduce the risk of developing type 2 diabetes. Diabetes Obese or overweight adults with prediabetes have a massive 94 percent increased risk of death.
Pharmaceutical giant Eli Lilly Phase 3 Clinical Trials Compared with weekly tirzepatide injections placebo Injections were administered to 1,032 participants over a period of approximately three years.
Not only did the drug reduce health risks, but those taking 15 mg per week experienced an average weight loss of 22.9%. body weight Over the course of the study, there was only a 2.1 percent decline in those treated with a placebo, compared with only a 2.1 percent decline in those treated with a placebo over the course of the study.
“Obesity is a chronic disease that puts approximately 900 million adults worldwide at risk of complications, including type 2 diabetes.” say Jeff Emick, senior vice president at Eli Lilly, which makes Zepbound;
“Tirzepatide reduced the risk of developing type 2 diabetes by 94% and produced sustained weight loss over three years of treatment.”
Keeping in mind that the details of the study have yet to be peer-reviewed and published, the results of this trial suggest that tirzepatide may be Type 2 diabetes It affects people who are already at high risk.
The chances of developing prediabetes into diabetes for people over 45 years of age vary depending on their individual circumstances, but in general: About 9 to 14 percentIt was Potentially We’re talking about tens of millions of people who could potentially delay or prevent the onset of serious metabolic diseases.
Like similar weight loss drugs developed in recent years, tirzepatide Mimic the effect A type of natural hormone, specifically GLP-1 (Glucagon-like peptide-1) and GIP (Glucose-dependent insulinotropic polypeptideThese hormones help improve blood sugar control and suppress appetite.
Tirzepatide has already attracted a lot of attention. Previous research raised it to at least the same level Ozempic drug In terms of weight loss, there are indications that these treatments may have health benefits. Beyond weight loss.
But these drugs are not without their drawbacks: Though approved for use by regulators, tirzepatide can cause some pretty serious side effects in certain people, including stomach and kidney problems, hypoglycemia, and serious side effects. Allergic reactions.
Questions remain about the long-term effectiveness of the treatment. After 17 weeks in the study, participants who stopped taking tirzepatide began to regain weight and progress to type 2 diabetes was recorded. When the 17-week period was included, the risk reduction dropped to 88 percent.
While these drugs, which include Zepbound and the related diabetes drug Munjaro, should not be taken without specialist advice, research suggests that even more significant treatments to reduce diabetes may be in the works. Risk of type 2 diabetes.
“These data support the potential clinical benefit of long-term treatment for patients with obesity and prediabetes.” say Emic.
This study Obesity Week 2024 It will be held in San Antonio in November.
